SummerHaven Investment Management LLC Acquires 1,660 Shares of Enhabit, Inc. (NYSE:EHAB)

SummerHaven Investment Management LLC raised its holdings in shares of Enhabit, Inc. (NYSE:EHAB) by 2.8% in the second quarter, Holdings Channel.com reports. The firm owned 61,508 shares of the company’s stock after purchasing an additional 1,660 shares during the period. SummerHaven Investment Management LLC’s holdings in Enhabit were worth $549,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in EHAB. Oppenheimer & Co. Inc. increased its position in Enhabit by 7.2% during the 1st quarter. Oppenheimer & Co. Inc. now owns 26,224 shares of the company’s stock valued at $306,000 after buying an additional 1,768 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Enhabit by 13.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 16,058 shares of the company’s stock valued at $166,000 after acquiring an additional 1,875 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Enhabit by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 37,950 shares of the company’s stock worth $443,000 after acquiring an additional 2,078 shares during the last quarter. Illinois Municipal Retirement Fund lifted its position in Enhabit by 10.7% in the 1st quarter. Illinois Municipal Retirement Fund now owns 33,042 shares of the company’s stock valued at $385,000 after acquiring an additional 3,193 shares in the last quarter. Finally, Gladius Capital Management LP purchased a new stake in Enhabit during the 2nd quarter valued at $31,000.

Analyst Ratings Changes

EHAB has been the topic of a number of research analyst reports. Leerink Partnrs raised Enhabit from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 14th. Jefferies Financial Group downgraded shares of Enhabit from a “buy” rating to a “hold” rating and dropped their price target for the company from $14.00 to $8.75 in a report on Thursday, May 9th. Bank of America decreased their price objective on shares of Enhabit from $9.00 to $8.00 and set an “underperform” rating for the company in a report on Thursday, June 27th. Finally, SVB Leerink raised shares of Enhabit from an “underperform” rating to a “market perform” rating and set a $8.50 target price for the company in a research report on Tuesday, May 14th. One investment analyst has rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $9.35.

Enhabit Stock Performance

Shares of Enhabit stock traded up $0.19 on Friday, hitting $8.21. 21,618 shares of the company’s stock were exchanged, compared to its average volume of 557,507. Enhabit, Inc. has a 1 year low of $7.12 and a 1 year high of $13.13. The company has a 50-day simple moving average of $9.03 and a 200-day simple moving average of $9.53. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.50 and a current ratio of 1.50. The stock has a market capitalization of $411.78 million, a PE ratio of -4.83, a PEG ratio of 1.58 and a beta of 1.85.

Enhabit (NYSE:EHAB) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.02. Enhabit had a positive return on equity of 1.43% and a negative net margin of 7.95%. The business had revenue of $260.60 million during the quarter, compared to analysts’ expectations of $265.99 million. During the same quarter in the prior year, the business posted $0.04 earnings per share. As a group, equities analysts anticipate that Enhabit, Inc. will post 0.24 EPS for the current year.

Enhabit Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.